Continuous in the Spotlight
Continuus Pharmaceuticals, a spin out from the Novartis-MIT Center for Continuous Manufacturing, describes itself as one of the few companies working specifically on continuous manufacturing; for drugmakers, continuous manufacturing efforts are secondary to R&D, but Continuus was established with the primary objective of shining a spotlight on continuous manufacturing. Bayan Takizawa, Chief Business Officer at Continuus Pharmaceuticals, tells us more.
Stephanie Sutton, Maryam Mahdi |
This article was published in our sister publication, The Small Molecule Manufacturer, which celebrates the field of small molecule drug development and manufacturing with interviews and articles focusing on success stories, equipment, and new processing techniques.
What’s the story behind Continuus Pharmaceuticals?
In 2007, Novartis and MIT embarked on a collaboration, targeting the continuous manufacture of small molecule drugs because they recognized how outdated batch processes were. They wanted to break away from conventional manufacturing and establish the best possible production system for these drugs. The end result was the Novartis-MIT Center for Continuous Manufacturing, which was a huge success. By 2011, they had constructed a pilot line at MIT that integrated both upstream and downstream components into a single continuous process. The team was able to take a 200-day batch process and cut it down to just two days, with the additional benefits of reduced footprint (approximately 90 percent reduction), reduced costs (30 to 50 percent), reduced environmental impact, and improved quality.
Continuus Pharmaceuticals is a spin out from the Novartis-MIT collaboration – and many of our team members and advisors were critical architects of the original project, including Professor Bernhardt Trout (MIT) and Tom Van Laar (former head of Global Tech Operations, Novartis). We have also now brought in other outside thought leaders as well. The goal? To bring the benefits of integrated continuous manufacturing to the broader pharma industry and transform small molecule manufacturing.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine